Biodesix INC 8-K filings

Biodesix, Inc. announced robust second quarter 2026 financial results, featuring a 34% increase in total revenue to $26.9 million and a 42% surge in Diagnostic Testing revenue.

Biodesix, Inc. held its 2026 annual meeting, where stockholders elected two Class III directors, approved executive compensation on an advisory basis, and ratified KPMG LLP as the independent auditor.

Biodesix, Inc. announced robust first quarter 2026 financial and operating results, driven by significant growth in both Diagnostic Testing and Development Services, leading to an increase in full-year revenue guidance.

Biodesix, Inc. announced strong fourth quarter and fiscal year 2025 results, surpassing revenue guidance and achieving its first quarter of positive Adjusted EBITDA.

Biodesix, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, reporting strong revenue growth and affirming Adjusted EBITDA positivity for Q4.

Biodesix, Inc. reported a robust third quarter with 20% revenue growth and improved gross margins, leading to an increased full-year 2025 revenue guidance.

Biodesix, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Biodesix, Inc. has completed a one-for-twenty reverse stock split and eliminated its Series A Non-Voting Convertible Preferred Stock to adjust its capital structure.

Biodesix, Inc. announced a one-for-twenty reverse stock split of its common stock, effective September 15, 2025, reducing outstanding shares from 156 million to 8 million.

Biodesix, Inc. announced strong second quarter 2025 financial and operating results, including a 12% revenue increase and reaffirmed full-year guidance, driven by growth in diagnostic testing and development services.

Biodesix held its annual meeting on May 20, 2025, where stockholders approved key proposals including a reverse stock split and an amendment to the employee stock purchase plan.

Biodesix reports a 21% increase in revenue and an 18% improvement in net loss for Q1 2025, while updating its 2025 revenue guidance to $80-85 million.

Charles Watts and Jack Schuler will resign from Biodesix's Board of Directors after the 2025 Annual Meeting of Stockholders, with Schuler transitioning to director emeritus.

Biodesix, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Biodesix reports a 45% increase in total revenue for fiscal year 2024, reaching $71.3 million, and forecasts $92-95 million for 2025.

Biodesix reports a strong finish to 2024 with a 45% increase in full-year revenue, driven by growth in both Lung Diagnostics and Biopharmaceutical Services.

Biodesix announced a 35% year-over-year increase in revenue for the third quarter of 2024, driven by strong growth in lung diagnostics.

Biodesix has raised its full-year revenue guidance to $70-72 million after experiencing significant growth in both its lung diagnostic and biopharmaceutical services sectors in the second quarter of 2024.

Biodesix announced a 51% revenue increase in Q2 2024 compared to Q2 2023, along with improved profitability metrics and an increased full-year revenue guidance.

Biodesix held its 2024 annual meeting where stockholders elected three Class I directors, ratified the appointment of KPMG LLP, and approved the conversion and issuance of Series A Preferred Stock.

Biodesix announced a 64% year-over-year increase in total revenue for the first quarter of 2024, driven by significant growth in lung diagnostic testing.

Biodesix has successfully priced a $55 million combined equity offering and private placement to support commercial expansion, product development, and research.

Biodesix achieved significant growth in lung diagnostic test volume and improved gross profit margins in 2023, with a positive outlook for 2024.